Trevena Announces Presentations at the 35th Annual Scientific Meeting of the American Pain Society

– Five Posters Highlight Clinical Performance of Oliceridine, Including Comparisons to Conventional Opioid Analgesics –

KING OF PRUSSIA, Pa.--(BUSINESS WIRE)-- Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands targeting G protein coupled receptors, today announced that the Company will present five posters the 35th Annual Scientific Meeting of the American Pain Society being held at the Austin Convention Center in Austin, Texas, May 11-14, 2016. The poster presentations highlight data on oliceridine, which has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration.

“The clinical and scientific research presented at the American Pain Society annual meeting highlight some of the key differentiating features observed in the oliceridine phase 2 program,” said David Soergel, M.D., chief medical officer at Trevena. “In these studies, head-to-head comparisons of oliceridine to morphine suggest the potential for oliceridine to offer rapid, powerful pain relief with improved safety and tolerability compared to conventional opioid analgesics.”

Details for the poster presentations are as follows:

**Title:** Rapid reduction in pain intensity with oliceridine (TRV130), a novel μ receptor G protein Pathway Selective modulator (µ-GPS), vs. Morphine  
**Poster Number:** 433  
**Poster Session:** 9:30-11:00am, Thursday May 12th

**Title:** Gastrointestinal tolerability with oliceridine (TRV130), a novel μ receptor G protein Pathway Selective modulator (µ-GPS), vs morphine  
**Poster Number:** 435  
**Poster Session:** 9:30-11:00am, Thursday May 12th

**Title:** Respiratory safety with oliceridine (TRV130), a novel μ receptor G protein pathway selective modulator (µ-GPS), vs morphine  
**Poster Number:** 432  
**Poster Session:** 3:45-5:15pm, Thursday May 12th
Title: Oliceridine (TRV130), a novel μ receptor G protein pathway selective modulator (μ-GPS), demonstrates a predictable relationship between plasma concentrations and pain relief. I: development of a pharmacokinetic/pharmacodynamic (PK/PD) model

Poster Number: 342
Poster Session: 3:45-5:15pm, Thursday May 12th

Title: Oliceridine (TRV130), a novel μ receptor G protein pathway selective modulator (μ-GPS), demonstrates a predictable relationship between plasma concentrations and pain relief. II: simulation of potential dosing regimens using a pharmacokinetic/pharmacodynamic (PK/PD) model

Poster Number: 343
Poster Session: 3:45-5:15pm, Thursday May 12th

About oliceridine

Oliceridine (TRV130) was designed to optimize mu opioid receptor pharmacology to deliver an improved analgesic profile, and has been granted Breakthrough Therapy designation by the U.S. Food & Drug Administration. Oliceridine is the first mu receptor G protein pathway selective modulator (muGPS) – a biased mu opioid receptor ligand that in preclinical studies activated pathways associated with analgesia while avoiding pathways that can promote respiratory depression and gastrointestinal dysfunction and limit analgesia. It is in Phase 3 development. In Phase 2, intravenous oliceridine demonstrated rapid and powerful analgesic efficacy with reduced frequency of opioid-related adverse events including nausea, vomiting, and hypoventilation compared to intravenous morphine. Trevena believes that oliceridine may offer an improved safety and tolerability profile compared to conventional opioid analgesics while providing powerful pain relief to patients. Trevena anticipates that the initial market opportunity for oliceridine will be in the acute care settings, with a focus on moderate to severe acute pain in the hospital.

About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified four biased ligand product candidates – oliceridine (TRV130) to treat moderate to severe acute pain intravenously (Phase 3), TRV027 to treat acute heart failure (Phase 2b), TRV734 to treat moderate to severe acute and chronic pain orally (Phase 1), and TRV250 for acute episodic migraine and other CNS disorders (preclinical).

Cautionary Note on Forward Looking Statements

Any statements in this press release about future expectations, plans and prospects for the Company, including statements about the Company’s strategy, future operations, clinical development of its therapeutic candidates, plans for potential future product candidates and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within
the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: uncertainties related to the Company’s intellectual property; the status, timing, costs, results and interpretation of the Company’s clinical trials, including whether oliceridine has the potential to offer rapid, powerful pain relief with improved safety and tolerability compared to conventional opioid analgesics like morphine; the uncertainties inherent in conducting clinical trials; whether interim results from a clinical trial will be predictive of the final results of the trial or results of early clinical trials, including the Phase 2 oliceridine studies, will be indicative of the results of future trials; expectations for regulatory approvals; availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements; other matters that could affect the availability or commercial potential of the Company’s therapeutic candidates; and other factors discussed in the Risk Factors set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings the Company makes with the SEC from time to time.

In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments may cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so, except as may be required by law.

View source version on businesswire.com:

Trevena, Inc.
Jonathan Violin, Ph.D.
Sr. Director, Investor Relations
(610) 354-8840 x231
jviolin@trevenainc.com

Source: Trevena, Inc.